Cagrilintide
clinical trialsAlso known as: AM833, NNC0174-0833
Cagrilintide (AM833, NNC0174-0833) is a long-acting amylin analog designed to activate the amylin receptor, which is expressed in the area postrema and other central nervous system regions involved in appetite regulation. By mimicking the satiety-signaling effects of endogenous amylin, cagrilintide delays gastric emptying and promotes a sustained reduction in food intake. Its extended half-life, achieved through fatty acid acylation, allows for once-weekly subcutaneous dosing, distinguishing it from native amylin and earlier analogs. Key research findings from Phase 1 and Phase 2 trials demonstrate dose-dependent weight loss, with reductions of up to 10.8% from baseline over 26 weeks in individuals with overweight or obesity. Notably, combination therapy with semaglutide (CagriSema) has shown additive or synergistic effects, achieving weight loss exceeding 15% in early studies, likely due to complementary mechanisms (amylin receptor agonism plus GLP-1 receptor agonism). Safety profiles are consistent with amylin-based therapies, including nausea, vomiting, and injection-site reactions, with no unexpected adverse signals. Clinically, cagrilintide represents a novel approach for obesity management, particularly as part of combination regimens to enhance efficacy beyond single-agent GLP-1 receptor agonists. Ongoing Phase 3 trials are evaluating its long-term safety, cardiovascular outcomes, and potential for weight maintenance. If approved, it could offer an additional option for patients with inadequate response to existing therapies, though regulatory decisions remain pending. For research purposes only — not medical advice.
Key data
C194H312N54O59S2Research & studies
Cagrilintide-semaglutide reduced body weight by 20.4% vs 3.0% with placebo (difference -17.3 percentage points, P<0.001).; Participants on the combination were significantly more likely to achieve weight-loss targets of 5%, 20%, 25%, and 30% or more.; Gastrointestinal adverse events occurred in 79.6% of the combination group vs 39.9% of the placebo group, but were mainly transient and mild-to-moderate.
All 15 GLP-1RAs effectively lowered HbA1c and fasting plasma glucose versus placebo.; Tirzepatide showed the largest HbA1c reduction (mean difference -2.10%) and fasting glucose reduction (-3.12 mmol/L).; CagriSema resulted in the highest weight loss (mean difference -14.03 kg), followed by tirzepatide (-8.47 kg).; Semaglutide significantly lowered LDL cholesterol and total cholesterol, but high-dose GLP-1RAs raised gastrointestinal safety concerns.
Frequently asked questions
What is Cagrilintide?
Cagrilintide (AM833, NNC0174-0833) is a long-acting amylin analog designed to activate the amylin receptor, which is expressed in the area postrema and other central nervous system regions involved in appetite regulation. By mimicking the satiety-signaling effects of endogenous amylin, cagrilintide delays gastric empty
How does Cagrilintide work?
Long-acting amylin analog in trials for obesity, including combination with semaglutide (CagriSema).
What is the research status of Cagrilintide?
Cagrilintide is currently classified as clinical trials, with 83 research references on record. This is for research purposes only and is not medical advice.
What is the molecular weight of Cagrilintide?
Cagrilintide has a molecular weight of approximately 4409 g/mol (formula C194H312N54O59S2).
Related peptides
Once-daily acylated GLP-1 receptor agonist for type 2 diabetes and chronic weight management.
Long-acting GLP-1 receptor agonist that improves glycemic control, slows gastric emptying, and reduces appetite.
Exendin-4-based GLP-1 receptor agonist from Gila monster venom; first-in-class incretin mimetic.
Dual GIP/GLP-1 receptor agonist delivering potent glucose lowering and weight reduction.
Once-weekly GLP-1 receptor agonist fused to an IgG4 Fc fragment for extended half-life.
Short-acting exendin-4-based GLP-1 receptor agonist with pronounced gastric-emptying delay.
Build on Cagrilintide data programmatically
Structured peptide data, semantic search, and AI summaries via one API.
Get a free API key